$LumiraDx (LMDXF.US)$@BadPaintrevisiting your Bill Gates post about him not selling his shares. It was announced while Lumiradx was on expert market I believe. Now I will say this, all the institutions that sold could have sold prior to expert market and bought back in during expert through an offshore entity. Zwanziger Ventures LLC perhaps? Can you dig more into Senvest for us? Off topic here a bit however I found this intriguing that Cobas was introduced in '94 however Roche only started divi...
$Esperion Therapeutics (ESPR.US)$Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share. Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
A Quick Review of my Trading Activities in this week ( 6 - 10 Jan 2025 ). Market Overview - US 10 Year Treasury yield is rising continuously because of high inflation expectation ( fear of high US tariffs ) and strong US economy ( low unemployment rate and strong consumers spending ). - US 10 Year Treasury yield is approaching 5% ( 5% was highest record since Fed hiked rate last 2 years ) and put large downward pressure to stock markets broadly. ( Yield curren...
$Esperion Therapeutics (ESPR.US)$Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry: 1. Unique Market Position in Statin Alternatives – Addressing Statin Intolerance: There are millions of statin...
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
AstraZeneca Stock Forum
Breakthrough in Bladder Cancer Treatment: AstraZeneca's IMFINZI Slashes Disease Progression Risk by 42%
Groundbreaking Digital Adventure Helps Kids Master Their Rare Kidney Disease Journey
Major Breakthrough: AstraZeneca's New Weapon Against Early-Stage Lung Cancer Enters Final Testing
Off topic here a bit however I found this intriguing that Cobas was introduced in '94 however Roche only started divi...
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
Market Overview
- US 10 Year Treasury yield is rising continuously because of high inflation expectation ( fear of high US tariffs ) and strong US economy ( low unemployment rate and strong consumers spending ).
- US 10 Year Treasury yield is approaching 5% ( 5% was highest record since Fed hiked rate last 2 years ) and put large downward pressure to stock markets broadly. ( Yield curren...
loading...
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
No comment yet